HUTCHMED (China) Limited
NASDAQ:HCM · NASDAQ Global Select
+$0.16 today
Vol 0.05M · Avg 0.04M
Cash Flow
Check whether earnings turn into cash
Use operating cash flow, capital spending, free cash flow, and financing activity to see how much value is left for reinvestment or owners.
Free Cash Flow
Net Income to FCF bridge
Analysis
Analysis will appear once cash flow data is available for this period.
Cash Flow Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Net Income | $458.1M +1114.2% | $37.7M -62.6% | $100.8M +128.0% | -$360.4M -115.7% | -$167.0M | $487.6M | $476.4M | $465.2M |
| Depreciation & Amortization | $13.3M +8.1% | $12.3M +50.4% | $8.2M -5.3% | $8.7M +20.5% | $7.2M | $374.2M | $1.2B | $631.8M |
| Deferred Income Tax | $0 | $0 +100.0% | -$102.8M | $0 +100.0% | -$115.1M | $1.4B | -$1.5B | $304.2M |
| Stock-Based Compensation | $15.3M -29.2% | $21.6M -41.0% | $36.6M +19.7% | $30.6M -27.2% | $42.0M | $489.0M | $354.6M | -$1.6B |
| Change in Working Capital | -$61.0M +1.8% | -$62.2M -187.4% | $71.1M +21.2% | $58.7M +80.9% | $32.5M | $350.4M | -$1.6B | $1.5B |
| Accounts Receivables | $28.9M +169.6% | -$41.6M -94.8% | -$21.3M -47.6% | -$14.5M +59.4% | -$35.6M | $592.6M | $1.3B | $626.2M |
| Inventory | $9.6M +1339.3% | -$772.0K -118.7% | $4.1M +119.5% | -$21.2M -32.6% | -$16.0M | $1.0B | $1.2B | $1.1B |
| Accounts Payables | $3.0M | $0 +100.0% | -$32.5M -208.7% | $29.9M +213.0% | $9.6M | $948.2M | -$1.5B | $433.0M |
| Other Working Capital | -$102.6M -417.3% | -$19.8M -116.4% | $120.9M +88.8% | $64.0M -14.1% | $74.5M | $567.4M | $1.3B | $601.0M |
| Other Non-Cash Items | -$490.6M -5342.8% | -$9.0M -108.6% | $105.3M +1807.2% | -$6.2M -67.4% | -$3.7M | $1.4B | -$1.5B | $300.0M |
| Operating Cash Flow | -$64.8M -13143.9% | $497.0K -99.8% | $219.3M +181.6% | -$268.6M -31.5% | -$204.2M | $7.2B | $8.9B | $10.5B |
| Capital Expenditures | -$14.2M +20.9% | -$17.9M +45.0% | -$32.6M +11.1% | -$36.7M -118.8% | -$16.8M | $664.0M | $1.4B | $697.6M |
| Acquisitions (Net) | $28.1K | $0 +100.0% | -$3.0M -1022.8% | $324.0K -99.8% | $159.1M | $937.0M | $1.1B | $1.3B |
| Purchases of Investments | -$2.7B -48.7% | -$1.8B -13.6% | -$1.6B -35.4% | -$1.2B +12.3% | -$1.4B | $444.2M | $1.4B | $1.3B |
| Sales of Investments | $2.7B +55.1% | $1.8B +28.9% | $1.4B -9.6% | $1.5B +64.8% | $921.4M | $822.2M | $318.2M | -$1.5B |
| Other Investing Activities | $0 -100.0% | $1.3M -95.7% | $29.5M +78.9% | $16.5M +1672.9% | $930.0K | $616.4M | $370.0M | $1.2B |
| Investing Cash Flow | -$29.5M +69.3% | -$96.1M +67.0% | -$291.1M -198.2% | $296.6M +196.8% | -$306.3M | $4.8B | $6.4B | $5.1B |
| Debt Repayment | $6.3M +11.9% | $5.6M -90.9% | $61.7M +772.9% | -$9.2M -1481.7% | -$579.8K | $680.8M | $759.2M | $1.1B |
| Common Stock Issued | $1.6M +100.3% | $790.0K -84.5% | $5.1M +2827.6% | $174.0K -100.0% | $717.3M | $778.8M | $946.8M | $812.4M |
| Common Stock Repurchased | $0 +100.0% | -$36.1M -297.6% | -$9.1M +81.1% | -$48.1M -76.1% | -$27.3M | $351.8M | -$1.6B | $1.5B |
| Dividends Paid | $0 | $0 | $0 +100.0% | -$87.4M +12.3% | -$99.7M | $535.2M | $613.6M | $692.0M |
| Other Financing Activities | $0 +100.0% | -$1.0M +89.0% | -$9.1M -114.7% | $61.8M +2.3% | $60.3M | -$1.6B | $1.3B | $1.1B |
| Financing Cash Flow | $7.9M +125.6% | -$30.7M -163.0% | $48.7M +158.8% | -$82.8M -112.7% | $650.0M | $12.2B | $13.9B | -$15.5B |
| Effect of Forex Changes | $3.8M +212.7% | -$3.4M +47.4% | -$6.5M +31.8% | -$9.5M -491.0% | $2.4M | $1.3B | $1.1B | $990.2M |
| Net Change in Cash | -$82.6M +36.3% | -$129.6M -336.6% | -$29.7M +53.8% | -$64.3M -145.3% | $141.9M | $3.2B | $4.9B | $6.5B |
| Free Cash Flow | -$79.0M -353.2% | -$17.4M -109.3% | $186.6M +161.1% | -$305.3M -38.1% | -$221.0M | $8.6B | -$16.8B | $11.1B |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Cidara Therapeutics, Inc.
CDTX
$5.61B
Scholar Rock Holding Corporation
NASDAQ:SRRK
$5.55B
Kiniksa Pharmaceuticals, Ltd.
NASDAQ:KNSA
$4.09B
Catalyst Pharmaceuticals, Inc.
NASDAQ:CPRX
$3.84B
IDEAYA Biosciences, Inc.
NASDAQ:IDYA
$2.92B
Adaptive Biotechnologies Corporation
NASDAQ:ADPT
$2.77B
Supernus Pharmaceuticals, Inc.
NASDAQ:SUPN
$2.55B
Bausch Health Companies Inc.
NYSE:BHC
$1.74B
Mineralys Therapeutics, Inc.
NASDAQ:MLYS
$1.69B
Perrigo Company plc
NYSE:PRGO
$1.37B
SEC Filings
Recent regulatory filings
No filings found.
Does HCM generate free cash flow?
HUTCHMED (China) Limited (HCM) generated -$79,013,420.00 of free cash flow in fiscal 2025.
How much operating cash flow does HCM produce?
Operating cash flow was -$64,828,000.00, before capital expenditures of $14.19M.
Explore More
Continue the stock analysis
Jump to another research area for this company.